Summit Trail Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.43M Sell
30,314
-12,690
-30% -$1.05M 0.03% 410
2025
Q4
$3.67M Sell
43,004
-157
-0.4% -$12.9K 0.06% 182
2025
Q3
$3.36M Buy
43,161
+7,064
+20% +$552K 0.05% 223
2025
Q2
$2.82M Buy
+36,097
New +$2.69M 0.05% 197
2024
Q4
Sell
-13,916
Closed -$918K 512
2024
Q3
$918K Buy
13,916
+103
+0.7% +$7.48K 0.02% 280
2024
Q2
$1.28M Buy
13,813
+102
+0.7% +$9.03K 0.03% 198
2024
Q1
$1.31M Buy
13,711
+189
+1% +$15.9K 0.03% 176
2023
Q4
$1.03M Buy
13,522
+192
+1% +$13.4K 0.03% 172
2023
Q3
$924K Buy
+13,330
New +$1.07M 0.03% 177
2023
Q2
Sell
-3,560
Closed -$295K 543
2023
Q1
$295K Buy
3,560
+657
+23% +$51.6K 0.01% 324
2022
Q4
$217K Buy
+2,903
New +$224K 0.01% 345
2022
Q3
Sell
-2,501
Closed -$238K 387
2022
Q2
$238K Buy
+2,501
New +$259K 0.01% 315
2022
Q1
Sell
-2,837
Closed -$368K 342
2021
Q4
$368K Buy
2,837
+311
+12% +$36.3K 0.02% 200
2021
Q3
$286K Buy
2,526
+164
+7% +$18.7K 0.02% 204
2021
Q2
$245K Buy
+2,362
New +$223K 0.02% 191
2020
Q4
Sell
-2,631
Closed -$211K 214
2020
Q3
$211K Buy
+2,631
New +$205K 0.04% 196
2018
Q1
Sell
-2,097
Closed -$86K 822
2017
Q4
$86K Buy
+2,097
New +$77K 0.01% 668

Other funds holding EW

Summit Trail Advisors's EW Position: Q1 2026 in Review

Summit Trail Advisors reduced its Edwards Lifesciences (EW) stake by 30% in Q1 2026, selling an estimated $1.05M and leaving 30,314 shares worth $2.43M. The position accounts for 0.03% of the portfolio, ranked #410.

Summit Trail Advisors first reported a position in EW in Q4 2017 and has held it in 17 quarters since. The position peaked at $3.67M in Q4 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Summit Trail Advisors held 30,314 shares of Edwards Lifesciences worth $2.43M as of Q1 2026.
  • Summit Trail Advisors sold 12,690 Edwards Lifesciences shares in Q1 2026, an estimated $1.05M.
  • Edwards Lifesciences made up 0.03% of Summit Trail Advisors's portfolio in Q1 2026, its #410 holding.
  • Summit Trail Advisors first reported a position in Edwards Lifesciences in Q4 2017 and has held it in 17 quarters since.
  • Summit Trail Advisors's Edwards Lifesciences position peaked at $3.67M in Q4 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.